| Style | Citing Format |
|---|---|
| MLA | Hashempour Z, et al.. "Worldwide Prevalence of Dyslipidemia in Diabetes: An Umbrella Overview of the Meta-Analysis Studies." Endocrine, Metabolic and Immune Disorders - Drug Targets, vol. 26, no. , 2026, pp. -. |
| APA | Hashempour Z, Esmaeili F, Tabatabaei Malazy O, Mosallanejad A, Panahi G (2026). Worldwide Prevalence of Dyslipidemia in Diabetes: An Umbrella Overview of the Meta-Analysis Studies. Endocrine, Metabolic and Immune Disorders - Drug Targets, 26(), -. |
| Chicago | Hashempour Z, Esmaeili F, Tabatabaei Malazy O, Mosallanejad A, Panahi G. "Worldwide Prevalence of Dyslipidemia in Diabetes: An Umbrella Overview of the Meta-Analysis Studies." Endocrine, Metabolic and Immune Disorders - Drug Targets 26, no. (2026): -. |
| Harvard | Hashempour Z et al. (2026) 'Worldwide Prevalence of Dyslipidemia in Diabetes: An Umbrella Overview of the Meta-Analysis Studies', Endocrine, Metabolic and Immune Disorders - Drug Targets, 26(), pp. -. |
| Vancouver | Hashempour Z, Esmaeili F, Tabatabaei Malazy O, Mosallanejad A, Panahi G. Worldwide Prevalence of Dyslipidemia in Diabetes: An Umbrella Overview of the Meta-Analysis Studies. Endocrine, Metabolic and Immune Disorders - Drug Targets. 2026;26():-. |
| BibTex | @article{ author = {Hashempour Z and Esmaeili F and Tabatabaei Malazy O and Mosallanejad A and Panahi G}, title = {Worldwide Prevalence of Dyslipidemia in Diabetes: An Umbrella Overview of the Meta-Analysis Studies}, journal = {Endocrine, Metabolic and Immune Disorders - Drug Targets}, volume = {26}, number = {}, pages = {-}, year = {2026} } |
| RIS | TY - JOUR AU - Hashempour Z AU - Esmaeili F AU - Tabatabaei Malazy O AU - Mosallanejad A AU - Panahi G TI - Worldwide Prevalence of Dyslipidemia in Diabetes: An Umbrella Overview of the Meta-Analysis Studies JO - Endocrine, Metabolic and Immune Disorders - Drug Targets VL - 26 IS - SP - EP - PY - 2026 ER - |